NEW YORK (GenomeWeb) – Following the release of the US Patent and Trademark Office's guidelines on how its examiners should interpret the US Supreme Court's decision in Association for Molecular Pathology et al. v. Myriad Genetics, life sciences industry players and legal experts are concerned that the patent office has overreached its authority.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.